What are the recent trends in market size and growth for the biosimilar monoclonal antibodies market?
The biosimilar monoclonal antibodies market size has grown rapidly in recent years. It will grow from $8.04 billion in 2024 to $9.25 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to patent expirations, growing awareness of biosimilars, government initiatives, increasing investment from pharmaceutical companies, and growing acceptance of biosimilars by clinicians and patients.
The biosimilar monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $12.79 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to rising biologic expenditure, biosimilar portfolio expansion, personalization of biosimilar therapy, and increasing public interest in biosimilars. Major trends in the forecast period include therapeutic expansion, personalized biosimilars, collaborations and partnerships, biosimilar autoinjectors and devices, biobetters.
Get Your Free Sample of The Global Biosimilar Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp
How have varous drivers impacted the growth of the biosimilar monoclonal antibodies market?
The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune diseases, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. For instance, in February 2024, according to reports published by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, a growing number of individuals in America are managing multiple chronic conditions, with 42% experiencing two or more, and 12% having five or more. Therefore, the prevalence of chronic diseases is expected to drive the growth of the biosimilar monoclonal antibodies market.
What are the primary segments of the biosimilar monoclonal antibodies market?
The biosimilar monoclonal antibodies market covered in this report is segmented –
1) By Type: Synthetic Chemicals, Biopharmaceuticals, Other Types
2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications
Subsegments:
1) By Synthetic Chemicals: Small Molecule Drugs, Chemical Synthesis Products
2) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals
3) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics
Order your report now for swift delivery
Which firms are leading the biosimilar monoclonal antibodies market?
Major companies operating in the biosimilar monoclonal antibodies market include Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy’s Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.
What are the top industry trends projected to impact the biosimilar monoclonal antibodies market?
Major companies operating in the biosimilar monoclonal antibodies market are focusing on developing cost-effective biosimilar therapies to gain a competitive advantage. These therapies are biologic medical products highly similar to already approved reference monoclonal antibodies, designed to provide affordable treatment options for various diseases, including cancer and autoimmune disorders. For instance, in 2022, Pfizer, a U.S.-based pharmaceutical company, launched Abrilada, a biosimilar to AbbVie’s Humira (adalimumab). Abrilada features a comparable efficacy and safety profile to the original while offering significant cost savings for patients and healthcare systems. Additionally, it benefits from a streamlined approval process and robust manufacturing capabilities, enhancing patient access to essential treatments. This trend reflects a broader industry shift towards addressing rising healthcare costs while maintaining high-quality therapeutic options for patients
Which geographic trends are shaping the biosimilar monoclonal antibodies market, and which region has the highest market share?
North America was the largest region in the biosimilar monoclonal antibodies market in 2024. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The Biosimilar Monoclonal Antibodies Market Report 2025 Offer?
The biosimilar monoclonal antibodies market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Biosimilar monoclonal antibodies refer to a member of the family of biosimilars. Large, intricate proteins are typically given as part of the treatment for conditions like cancer or rheumatoid arthritis. They are employed by the immune system to recognize and destroy foreign substances, including bacteria, viruses, and others.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3412
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
